KRAS and non-small cell lung carcinoma: In the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC), SMARCA4-mutated NSCLC patients have an approximate 30% incidence of KRAS/SMARCA4 co-mutations [20].